NEW YORK (GenomeWeb News) – Link Technologies has licensed diagnostic reagent-related technology from the University of Manchester that it intends to market worldwide, the Scottish company said today.

Under the agreement with the University of Manchester Intellectual Property Limited, the firm acquired the rights to make and sell oligonucleotide reagents using the university's exciplex technology. It also will collaborate with the university to further develop the existing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.